Integrins in angiogenesis

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 63-73

  Alavi, Alireza S ^a   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell Invasion; Extracellular Matrix; Integrin

Indexed keywords

EID: 79952752543     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_6     Document Type: Chapter

References (142)

1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87(7):1153-5.
2. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. The Journal of cell biology 1989;109(1):317-30.
3. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983;221(4607):281-3.
4. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69(1):11-25.
5. Sastry SK, Burridge K. Focal adhesions: a nexus for intracel-lular signaling and cytoskeletal dynamics. Experimental cell research 2000;261(1):25-36.
6. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Current opinion in cell biology 2003;15(5): 572-82.
7. Boudreau N, Andrews C, Srebrow A, Ravanpay A, Cheresh DA. Induction of the angiogenic phenotype by Hox D3. The Journal of cell biology 1997;139(1):257-64.
8. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401(6754):670-7.
9. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Current opinion in cell biology 1992;4(5):766-71.
10. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endo-thelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proceedings of the National Academy of Sciences of the United States of America 1997;94(25): 13612-7.
11. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogen-esis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. The American journal of pathology 2000;156(4):1345-62.
12. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del Zoppo GJ. Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. The American journal of pathology 1996;149(1):37-44.
13. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264(5158): 569-71.
14. Garmy-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R, Varner J. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. The Journal of clinical investigation 2005;115(6): 1542-51.
15. Hiran TS, Mazurkiewicz JE, Kreienberg P, Rice FL, LaFlamme SE. Endothelial expression of the alpha6beta4 integrin is negatively regulated during angiogenesis. Journal of cell science 2003;116(Pt 18):3771-81.
16. Yokosaki Y, Palmer EL, Prieto AL, et al. The integrin alpha 9 beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin. The Journal of biological chemistry 1994;269(43):26691-6.
17. Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. The Journal of biological chemistry 1996;271(45):28485-91.
18. Taooka Y, Chen J, Yednock T, Sheppard D. The integrin alpha-9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. The Journal of cell biology 1999;145(2):413-20.
19. Huang XZ, Wu JF, Ferrando R, et al. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Molecular and cellular biology 2000;20(14):5208-15.
20. Francis SE, Goh KL, Hodivala-Dilke K, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arteriosclerosis, thrombosis, and vascular biology 2002;22(6):927-33.
21. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development (Cambridge, England) 1993;119(4):1093-105.
22. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vascu-logenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998;95(4):507-19.
23. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF. beta8 integrins are required for vascular morphogenesis in mouse embryos. Development (Cambridge, England) 2002;129(12):2891-903.
24. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombas-thenia showing placental defects and reduced survival. The Journal of clinical investigation 1999;103(2):229-38.
25. Huang X, Griffiths M, Wu J, Farese RV, Jr., Sheppard D. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Molecular and cellular biology 2000;20(3):755-9.
26. Huang XZ, Wu JF, Cass D, et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. The Journal of cell biology 1996;133(4):921-8.
27. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nature medicine 2002;8(1):27-34.
28. Reynolds LE, Conti FJ, Lucas M, et al. Accelerated re-epithe-lialization in beta3-integrin-deficientmice is associated with enhanced TGF-beta1 signaling. Nature medicine 2005;11(2): 167-74.
29. Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RO. Increased primary tumor growth in mice null for beta3-or beta3/beta5-integrins or selectins. Proceedings of the National Academy of Sciences of the United States of America 2004;101(3):763-8.
30. Weis SM, Lindquist JN, Barnes LA, et al. Cooperation between VEGF and {beta}3 integrin during cardiac vascular development. Blood 2006.
31. Schneller M, Vuori K, Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. The EMBO journal 1997;16(18):5600-7.
32. Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. The Journal of biological chemistry 2000;275(51):39867-73.
33. Bergers G, Brekken R, McMahon G, et al. Matrix metallopro-teinase-9 triggers the angiogenic switch during carcinogenesis. Nature cell biology 2000;2(10):737-44.
34. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85(5): 683-93.
35. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92(3):391-400.
36. Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angio-genesis and tumor growth in vivo. The Journal of cell biology 2001;154(5):1069-79.
37. Clark RA, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. The American journal of pathology 1996;148(5): 1407-21.
38. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochimica et biophysica acta 1989;948(3): 305-26.
39. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Laboratory investigation; a journal of technical methods and pathology 1987;57(6):673-86.
40. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine 1986;315(26):1650-9.
41. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. The American journal of pathology 2000;156(5):1673-83.
42. van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Annals of the New York Academy of Sciences 2001;936:426-37.
43. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin {alpha}v{beta}3 Rescues Melanoma Cells from Apoptosis in Three-Dimensional Dermal Collagen. In; 1994:8856-60.
44. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Foug-erolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. The American journal of pathology 2002;160(1): 195-204.
45. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. The Journal of cell biology 1998;140(5):1255-63.
46. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unli-gated integrins. The Journal of cell biology 2001;155(3):459-70.
47. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. The Journal of cell biology 1998;141(4):1083-93.
48. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. The Journal of clinical investigation 1996;98(2):426-33.
49. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270(5241):1500-2.
50. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitro-nectin receptor-type integrins inhibits retinal neovascularization. Nature medicine 1996;2(5):529-33.
51. Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. The Journal of biological chemistry 2001;276(34):31959-68.
52. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. Journal of cell science 2002;115(Pt 19):3729-38.
53. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nature reviews 2006;6(6):449-58.
54. Stupack DG, Teitz T, Potter MD, et al. Potentiation of neuroblas-toma metastasis by loss of caspase-8. Nature 2006;439(7072): 95-9.
55. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. The Journal of biological chemistry 2000;275(31):23745-50.
56. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285(5430):1028-32.
57. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. The Journal of clinical investigation 1999;103(1):47-54.
58. Jan Y, Matter M, Pai JT, et al. A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell 2004;116(5):751-62.
59. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. The Journal of biological chemistry 1999;274(17):11721-6.
60. Frisch SM, Screaton RA. Anoikis mechanisms. Current opinion in cell biology 2001;13(5):555-62.
61. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. The Journal of clinical investigation 1995;96(4):1815-22.
62. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proceedings of the National Academy of Sciences of the United States of America 1996;93(18):9764-9.
63. Stromblad S, Fotedar A, Brickner H, et al. Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. The Journal of biological chemistry 2002;277(16): 13371-4.
64. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer cell 2003;3(6):589-601.
65. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membranederived tumstatin. The Journal of biological chemistry 2001;276(18):15240-8.
66. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proceedings of the National Academy of Sciences of the United States of America 2003;100(8):4766-71.
67. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295(5552):140-3.
68. Stupack DG. Integrins as a distinct subtype of dependence receptors. Cell death and differentiation 2005;12(8):1021-30.
69. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability. Molecular Cell 1999;4(6):915-24.
70. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301(5629):94-6.
71. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296(5577): 2404-7.
72. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature reviews 2003;3(6):422-33.
73. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer research 2000;60(9):2520-6.
74. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer research 2000;60(19):5410-3.
75. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277-85.
76. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79(2):315-28.
77. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. The Journal of biological chemistry 2000;275(2):1209-15.
78. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. The Journal of biological chemistry 2000;275(11): 8051-61.
79. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer research 2005;65(10):3967-79.
80. Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. The Journal of biological chemistry 2002;277(31):27872-9.
81. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2001;98(3):1024-9.
82. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS letters 2000;486(3):247-51.
83. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. The Journal of biological chemistry 2000;275(28):21340-8.
84. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nature medicine 2002;8(9):918-21.
85. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochemical and biophysical research communications 1999;258(2):345-52.
86. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. The EMBO journal 1999;18(16): 4414-23.
87. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proceedings of the National Academy of Sciences of the United States of America 2005;102(8):2934-9.
88. Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS letters 2002;519 (1-3):147-52.
89. Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2,-9, and-13. The Journal of biological chemistry 2003;278(25):22404-11.
90. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proceedings of the National Academy of Sciences of the United States of America 2000;97(22):12227-32.
91. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. International journal of cancer 2000;86(1):15-23.
92. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell and tissue research 2003;314(1):15-23.
93. Jain RK, Booth MF. What brings pericytes to tumor vessels? The Journal of clinical investigation 2003;112(8):1134-6.
94. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development (Cambridge, England) 1999;126(14):3047-55.
95. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. The Journal of cell biology 2001;153(3):543-53.
96. Mecham RP, Stenmark KR, Parks WC. Connective tissue production by vascular smooth muscle in development and disease. Chest 1991;99(3 Suppl):43S-7S.
97. Tan EM, Glassberg E, Olsen DR, et al. Extracellular matrix gene expression by human endothelial and smooth muscle cells. Matrix (Stuttgart, Germany) 1991;11(6):380-7.
98. Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos. Developmental biology 2006;293(1):165-77.
99. Goldfinger LE, Han J, Kiosses WB, Howe AK, Ginsberg MH. Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration. The Journal of cell biology 2003;162(4):731-41.
100. Sengbusch JK, He W, Pinco KA, Yang JT. Dual functions of [alpha]4[beta]1 integrin in epicardial development: initial migration and long-term attachment. The Journal of cell biology 2002;157(5):873-82.
101. Kassner PD, Hemler ME. Interchangeable alpha chain cytoplasmic domains play a positive role in control of cell adhesion mediated by VLA-4, a beta 1 integrin. The Journal of experimental medicine 1993;178(2):649-60.
102. Pinco KA, He W, Yang JT. alpha4beta1 integrin regulates lamellipodia protrusion via a focal complex/focal adhesion-independent mechanism. Molecular biology of the cell 2002;13(9):3203-17.
103. Nishiya N, Kiosses WB, Han J, Ginsberg MH. An alpha4 integrin-paxillin- Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nature cell biology 2005;7(4):343-52.
104. Sheppard AM, Onken MD, Rosen GD, Noakes PG, Dean DC. Expanding roles for alpha 4 integrin and its ligands in development. Cell adhesion and communication 1994;2(1):27-43.
105. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59(6):1203-11.
106. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60(4):577-84.
107. Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990;60(1):53-61.
108. Jain RK, Duda DG. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer cell 2003;3(6):515-6.
109. Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogen-esis in a mouse model. The Journal of clinical investigation 2004;114(3):330-8.
110. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lym-phangiogenesis and hemangiogenesis in inflammatory neovas-cularization via macrophage recruitment. The Journal of clinical investigation 2004;113(7):1040-50.
111. Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 2004;172(8):5034-40.
112. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer research 2006;66(4):2146-52.
113. Jin H, Aiyer A, Su J, et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovascula-ture. The Journal of clinical investigation 2006;116(3):652-62.
114. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogen-esis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer cell 2003;4(4):277-89.
115. Dietrich J, Lacagnina M, Gass D, et al. EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy. Nature medicine 2005;11(3):277-83.
116. Haubner R, Schmitt W, Holzemann G, Goodman SL, Jonczyk A, Kessler H. Cyclic RGD Peptides Containing β-Turn Mimetics. In; 1996:7881-91.
117. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. International journal of cancer 2000;87(5):716-23.
118. Miller WH, Keenan RM, Willette RN, Lark MW. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). Drug Discov Today 2000;5(9):397-408.
119. Goodman SL, Holzemann G, Sulyok GA, Kessler H. Nanomo-lar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. Journal of medicinal chemistry 2002;45(5):1045-51.
120. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antian-giogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6(8):3056-61.
121. McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11(21): 7851-60.
122. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. Journal of experimental therapeutics & oncology 2006;5(4):273-86.
123. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. International journal of cancer 2004;110(3):326-35.
124. Jayson GC, Mullamitha S, Ton C, et al. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to {alpha}v inte-grins, in patients with solid tumors. In; 2005:3113.
125. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs 2003;4(6):741-5.
126. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharma-cokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003;39(7):917-26.
127. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer research 1998;58(9):1930-5.
128. Reinmuth N, Liu W, Ahmad SA, et al. Alphavbeta3 integ-rin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer research 2003;63(9):2079-87.
129. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaV-beta3-targeted magnetic resonance imaging. Nature medicine 1998;4(5):623-6.
130. Winter PM, Morawski AM, Caruthers SD, et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With {alpha}v{beta}3-Integrin- Targeted Nanoparticles. In; 2003:2270-4.
131. Chen X, Park R, Shahinian AH, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nuclear medicine and biology 2004;31(2):179-89.
132. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjugate chemistry 2004;15(1):41-9.
133. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate chemistry 2004;15(1):61-9.
134. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer research 2001;61(5):1781-5.
135. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and In vivo Characterization of 64Cu-Labeled Abegrin TM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3. Cancer research 2006;66(19):9673-81.
136. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer biotherapy & radiopharmaceuticals 2002;17(6):641-6.
137. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer research 2002;62(21):6146-51.
138. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer research 2004;64(21):8009-14.
139. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279(5349):377-80.
140. Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003;91(1-2):115-22.
141. Kasono K, Blackwell JL, Douglas JT, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999;5(9):2571-9.
142. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic acids research 2004;32(19): e149.